Global Blood Therapeutics Balance Sheet Health
Financial Health criteria checks 2/6
Global Blood Therapeutics has a total shareholder equity of $118.4M and total debt of $581.9M, which brings its debt-to-equity ratio to 491.7%. Its total assets and total liabilities are $870.4M and $752.1M respectively.
Key information
491.7%
Debt to equity ratio
US$581.95m
Debt
| Interest coverage ratio | n/a |
| Cash | US$517.16m |
| Equity | US$118.36m |
| Total liabilities | US$752.08m |
| Total assets | US$870.44m |
Recent financial health updates
Global Blood Therapeutics (NASDAQ:GBT) Is Making Moderate Use Of Debt
Jun 07
Is Global Blood Therapeutics (NASDAQ:GBT) Using Too Much Debt?
Feb 24Despite Lacking Profits Global Blood Therapeutics (NASDAQ:GBT) Seems To Be On Top Of Its Debt
Nov 03Global Blood Therapeutics (NASDAQ:GBT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Jul 08Is Global Blood Therapeutics (NASDAQ:GBT) A Risky Investment?
Mar 18Health Check: How Prudently Does Global Blood Therapeutics (NASDAQ:GBT) Use Debt?
Dec 03Recent updates
Global Blood Therapeutics expects to complete Pfizer deal in early October
Sep 30Global Blood Therapeutics: Pfizer Acquisition Signals Increasing M/A Deals
Sep 16Pfizer said to have had bidding war with Johnson & Johnson for Global Blood
Aug 24What Pfizer Is Getting Through The Acquisition Of Global Blood Therapeutics
Aug 08Global Blood Therapeutics to expand access to its sickle cell disease treatment in Brazil
Jul 14GBT begins phase 2/3 clinical trial of GBT601 to treat sickle cell disease
Jun 29Global Blood Therapeutics: Powerhouse Of The Future
Jun 21Global Blood Therapeutics (NASDAQ:GBT) Is Making Moderate Use Of Debt
Jun 07Global Blood Therapeutics: Hitting A Growth Inflection
Apr 12Global Blood Therapeutics: Changing My Strategy After Recent Earnings
Mar 12Is Global Blood Therapeutics (NASDAQ:GBT) Using Too Much Debt?
Feb 24Global Blood Therapeutics: Revisiting A Stellar Grower
Dec 25IBI Research On Global Blood Therapeutics: Galvanized For Growth
Nov 30Despite Lacking Profits Global Blood Therapeutics (NASDAQ:GBT) Seems To Be On Top Of Its Debt
Nov 03Global Blood Therapeutics: It Might Be Time To Buy The Dip
Oct 24Global Blood Therapeutics: Attempting To Classify The Investment
Aug 07Global Blood Therapeutics (NASDAQ:GBT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Jul 08Shareholders May Not Be So Generous With Global Blood Therapeutics, Inc.'s (NASDAQ:GBT) CEO Compensation And Here's Why
Jun 12Global Blood Therapeutics announces employment inducement grants
Jun 04Global Blood Therapeutics: Increasing Specialization In SCD
May 09Is Global Blood Therapeutics (NASDAQ:GBT) A Risky Investment?
Mar 18Breakeven On The Horizon For Global Blood Therapeutics, Inc. (NASDAQ:GBT)
Feb 20
Did Business Growth Power Global Blood Therapeutics' (NASDAQ:GBT) Share Price Gain of 152%?
Jan 25Have Insiders Been Buying Global Blood Therapeutics, Inc. (NASDAQ:GBT) Shares?
Dec 29Health Check: How Prudently Does Global Blood Therapeutics (NASDAQ:GBT) Use Debt?
Dec 03Financial Position Analysis
Short Term Liabilities: GBT's short term assets ($640.0M) exceed its short term liabilities ($93.1M).
Long Term Liabilities: GBT's short term assets ($640.0M) do not cover its long term liabilities ($659.0M).
Debt to Equity History and Analysis
Debt Level: GBT's net debt to equity ratio (54.7%) is considered high.
Reducing Debt: Insufficient data to determine if GBT's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GBT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if GBT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.